tradingkey.logo

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

ReutersMar 25, 2025 11:34 AM

- Relmada Therapeutics Inc RLMD.O:

  • RELMADA THERAPEUTICS LICENSES PHASE 2 BLADDER CANCER CANDIDATE, NDV-01, FROM TRIGONE PHARMA, LTD.

  • RELMADA- UNDER DEAL,CO TO MAKE $3.5 MILLION UPFRONT PAYMENT AND ISSUE 3,017,420 SHARES OF COMMON STOCK

  • RELMADA- TO PAY UP TO $200 MILLION IN DEVELOPMENT, REGULATORY,SALES MILESTONES PENDING SUCCESSFUL COMMERCIALIZATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI